Discovery of potent iminoheterocycle BACE1 inhibitors.

The synthesis of a series of iminoheterocycles and their structure-activity relationships (SAR) as inhibitors of the aspartyl protease BACE1 will be detailed. An effort to access the S3 subsite directly from the S1 subsite initially yielded compounds with sub-micromolar potency. A subset of compounds from this effort unexpectedly occupied a different binding site and displayed excellent BACE1 affinities. Select compounds from this subset acutely lowered Aβ40 levels upon subcutaneous and oral administration to rats.

[1]  J. Winkler,et al.  Stereoselective synthesis of the tetracyclic core of manzamine via the vinylogous amide photocycloaddition cascade , 1998 .

[2]  D. Liotta,et al.  A Facially-Selective Protonation Controls the Stereochemistry of a Key Intermediate in the Synthesis of 1.beta.-Methylcarbapenems , 1994 .

[3]  Lingyan Wang,et al.  Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. , 2010, Journal of medicinal chemistry.

[4]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[5]  C. Selve,et al.  Reduction d'azides en amines par le formiate d'ammonium par “Transfert d'Hydrogene Catalyse” (CTH) , 1983 .

[6]  G. Higgins,et al.  Age-progressing cognitive impairments and neuropathology in transgenic CRND8 mice , 2005, Behavioural Brain Research.

[7]  P. Keitz,et al.  Design and Synthesis of a Conformationally Restricted Cysteine Protease Inhibitor , 1994 .

[8]  Rajiv Chopra,et al.  Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. , 2010, Journal of medicinal chemistry.

[9]  Suresh Babu,et al.  Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction. , 2012, ACS medicinal chemistry letters.

[10]  Michael Czarniecki,et al.  Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. , 2010, Journal of medicinal chemistry.

[11]  Paul Zuck,et al.  Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase. , 2008, Journal of medicinal chemistry.

[12]  Lynn A. Hyde,et al.  Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. , 2012, Bioorganic & medicinal chemistry letters.

[13]  Ying-zi Xu,et al.  Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011) , 2012, Expert opinion on therapeutic patents.

[14]  M. Varasi,et al.  Nicotinoyl azide (NCA)-mediated Mitsunobu reaction: An expedient one-pot transformation of alcohols into azides , 2004 .

[15]  Gianni Chessari,et al.  Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. , 2007, Journal of medicinal chemistry.

[16]  Walter A. Korfmacher,et al.  Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. , 2001, Rapid communications in mass spectrometry : RCM.

[17]  I. Coldham,et al.  Synthesis of the ABC ring system of manzamine A. , 2002, The Journal of organic chemistry.

[18]  E. Corey,et al.  Diverse pathways for the palladium(II)-mediated oxidation of olefins by tert-butylhydroperoxide. , 2002, Organic letters.

[19]  Clive McCarthy,et al.  Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.